Regulatory aspects for competitive Generic Therapies in USA

  • Himani Patel Isazi Pharma and Techno Consultancy Private Limited
  • Iva Dhulia
  • Umesh Dobariya
  • Nidhi Pardeshi
  • Yogesh Katariya
DOI https://doi.org/10.22270/ijdra.v9i2.463

Abstract

The FDA Reauthorization Act (FDARA) of 2017 lets generic companies ask for expedited review and 180-day exclusivity for a Competitive Generic Therapies (CGT)-designated product. (1)


FDA guidance for industry on Competitive Generic Therapies (CGT) provides keen information for generic drug manufacturers who want to develop a drug with inadequate generic competition. This guideline is specially published for generic players. If you are a generic manufacturer or sponsor, this will



  • Explain the process and criteria to request and designate a drug as a CGT.

  • Information on the actions FDA may take to expedite the development and review of ANDAs designated as CGT.

  • Implementation of 180-day exclusivity period for certain first approved applicants that submit ANDAs for CGTs. (1)

Keywords: FDA Reauthorization Act (FDARA), FD&C Act, ANDA, Competitive Generic Therapy, Inadequate Generic Competition

Downloads

Download data is not yet available.

References

1. Competitive Generic Therapies [Internet]. USFDA; 2020 [cited 2021 Apr 07]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies
2. Competitive Generic Therapies, Guidance for Industry [Internet]. USFDA; 2020 [cited 2021 Apr 01]. Available from: https://www.fda.gov/media/136063/download
3. Federal Food, Drug, And Cosmetic Act, Section 506H(e)(2)(A) [Internet]. Federal Food, Drug, And Cosmetic Act; [updated 2021 Jan 05; cited 2021 Apr 02]. Available from: https://www.govinfo.gov/content/pkg/COMPS-973/pdf/COMPS-973.pdf
4. Federal Food and Drug Reauthorization Act, Section 803 [Internet]. Federal Food and Drug Reauthorization Act; 2017 Aug 18 [cited 2021 Apr 01]. Available from: https://www.congress.gov/115/plaws/publ52/PLAW-115publ52.pdf
5. Controlled Correspondence Related to Generic Drug Development Guidance for Industry, Guidance for Industry [Internet]. USFDA; 2020 [cited 2021 Apr 07]. Available from: https://www.fda.gov/media/109232/download
6. ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence), Guidance for Industry [Internet]. USFDA; 2017 [cited 2021 Apr 03]. Available from: https://www.fda.gov/media/105794/download
7. Federal Food and Drug Reauthorization Act, Section 803 [Internet]. Federal Food and Drug Reauthorization Act. 2017 Aug 18 [cited 2021 Apr 02]. Available from: https://www.congress.gov/115/plaws/publ52/PLAW-115publ52.pdf
8. Alan Minsk, Seth Ray, Competitive Generic Therapies: FDA Issues Final Guidance [Internet]. Jdsupra; 2020 Jun 03 [cited 2021 Apr 01]. Available from: https://www.jdsupra.com/legalnews/competitive-generic-therapies-fda-28268/
9. Thomas Sullivan, FDA Publishes Final Guidance on Competitive Generic Therapies, Policy and Medicine, Rockpointe Publications [Internet] policymed; 2020 [updated 2020 May 06, cited 2021 April 06]. Available from: https://www.policymed.com/2020/05/fda-publishes-final-guidance-on-competitive-generic-therapies.html
10. Sailesh K. Patel, Thomas A. Rammer II, Competitive Generic Therapy Exclusivity Offers Benefits, Schiff Hardin [Internet]. Schiffhardin; 2019 Apr 25 [cited 2021 Apr 06]. Available from: https://www.schiffhardin.com/insights/publications/2019/competitive-generic-therapy-exclusivity-offers-benefits
11. Prasad V, Kale P. Complex Generics: Opportunities & Challenges. Int J Drug Reg Affairs [Internet]. 2018 Feb 13 [cited 2021 Jun 15];4(3):1-10. Available from: http://ijdra.com/index.php/journal/article/view/184
12. M SK, Katamreddy JD, P JR. A review on ANDA submission requirements for Generic drugs: “Paragraph IV certification” as per FDA CDER guidelines. Int J Drug Reg Affairs [Internet]. 2018 Sep 15 [cited 2021 Jun 15];6(3):5-12. Available from: http://ijdra.com/index.php/journal/article/view/260
13. Shah S, Badjatya JK. Preliminary requirement for filing application in US. Int J Drug Reg Affairs [Internet]. 2018 Dec 20 [cited 2021 Jun 15];6(4):1-. Available from: http://ijdra.com/index.php/journal/article/view/276
14. Kashyap P, Duggal E, Budhwar P, Badjatya JK. MARKETING AUTHORIZATION OF GENERIC DRUG: GLOBAL ISSUE AND CHALLENGES. Int J Drug Reg Affairs [Internet]. 2013 Oct 31 [cited 2021 Jun 15];1(3):1-6. Available from: http://ijdra.com/index.php/journal/article/view/5
Statistics
279 Views | 238 Downloads
How to Cite
Patel, H., I. Dhulia, U. Dobariya, N. Pardeshi, and Y. Katariya. “Regulatory Aspects for Competitive Generic Therapies in USA”. International Journal of Drug Regulatory Affairs, Vol. 9, no. 2, June 2021, pp. 16-19, doi:10.22270/ijdra.v9i2.463.
Issue
Vol 9 No 2 (2021): VOLUME 9, ISSUE 2, 2021
Section
Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.

I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.

Download link for COPYRIGHT FORM